Skip to main content
. 2005 Jun;49(6):2260–2266. doi: 10.1128/AAC.49.6.2260-2266.2005

TABLE 6.

Treatment-emergent, drug-related adverse events in patients with CSSTIs treated with linezolid or comparator drugs

Adverse event(s) No. (%) of patients treated with:
P value
Linezolid (N = 592) Vancomycina (N = 588)
Drug-related events 131 (22.1) 121 (20.6) 0.516
Serious adverse events 2 (<1) 8 (1.4) 0.064
Most common events (≥1% in either group)
    Anemia 7 (1.2) 10 (1.7) 0.476
    Diarrhea 31 (5.2) 9 (1.5) 0.0006
    Headache 10 (1.7) 4 (0.7) 0.177
    Nausea 24 (4.1) 8 (1.4) 0.006
    Pruritus 6 (1.0) 10 (1.7) 0.328
    Rash 3 (0.5) 16 (2.7) 0.002
    Thrombocytopenia 21 (3.5) 0 <0.001
    Vomiting 8 (1.4) 5 (0.9) 0.579
a

Patients could be switched to nafcillin, oxacillin, dicloxacillin, or flucloxacillin based on culture results.

HHS Vulnerability Disclosure